# Monoclonal Antibody Therapy in Treating Patients With Lymphoproliferative Disorder Associated With Immunosuppression Therapy

> **NCT00003716** · PHASE2 · COMPLETED · sponsor: **Stanford University** · enrollment: 25 (actual)

## Conditions studied

- Lymphoma

## Interventions

- **BIOLOGICAL:** rituximab

## Key facts

- **NCT ID:** NCT00003716
- **Lead sponsor:** Stanford University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1998-03
- **Primary completion:** 2007-01
- **Final completion:** 2007-01
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2022-05-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00003716

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00003716, "Monoclonal Antibody Therapy in Treating Patients With Lymphoproliferative Disorder Associated With Immunosuppression Therapy". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00003716. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*